{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:42:41Z","timestamp":1786725761666,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a highly aggressive lymphoma with a poor response to chemotherapy, frequent relapses, low overall survival, and poor prognosis, and is the most common form of PTCL. For relapsed\/refractory (R\/R) PTCLs, the efficacy of traditional chemotherapy is even worse, so clinical trials and new drugs become their therapeutic hope. The patient was a 43-year-old woman who complained of enlarged superficial lymph nodes (submandibular, neck, axillary, epitrochlear, and groin) and progressive aggravation of skin lesions, facial and limb edema, and subcutaneous masses. Histological analyses of lymph nodes and skin biopsy were suggestive of PTCL-NOS. The patient experienced failure of six lines of therapy, including multiple cycles of chemotherapy, chidamide, and BCL-2 inhibitors therapy, surprisingly, has a good response to PD-1 inhibitor combined with decitabine. We intend to provide some references for clinical practice.<\/jats:p>","DOI":"10.4103\/jcrt.jcrt_1458_22","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T10:11:19Z","timestamp":1703844679000},"page":"1680-1684","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature"],"prefix":"10.4103","volume":"19","author":[{"given":"Xiao","family":"Han","sequence":"first","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Wen","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"key":"R1-20260511","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.4103\/0973-1482.189235","article-title":"Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma[J]","volume":"12","author":"Bo","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"R2-20260511","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma[J]","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"R3-20260511","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4103\/0973-1482.140789","article-title":"Primary laryngeal peripheral T-cell lymphoma--An autopsy report with review of literature","volume":"11","author":"Padhi","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"R4-20260511","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified[J]","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"key":"R5-20260511","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid neoplasms[J]","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"R6-20260511","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/IJPM.IJPM_405_17","article-title":"Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India[J]","volume":"61","author":"Lakshmanan","year":"2018","journal-title":"Indian J Pathol Microbiol"},{"key":"R7-20260511","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12185-010-0513-0","article-title":"Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma[J]","volume":"91","author":"Asano","year":"2010","journal-title":"Int J Hematol"},{"key":"R8-20260511","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1080\/10428194.2017.1300894","article-title":"The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma[J]","volume":"58","author":"Chen","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"R9-20260511","article-title":"NCCN clinical practice guidelines in oncology\u2014T-Cell Lymphomas (Version 1. 2023) [S]","author":"Steven","year":"2023","journal-title":"J Nat Compr Canc Netw"},{"key":"R10-20260511","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.14473","article-title":"How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: Current practice and a glimpse into the future[J]","volume":"176","author":"Schmitz","year":"2017","journal-title":"Br J Haematol"},{"key":"R11-20260511","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma[J]","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"key":"R12-20260511","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4103\/jcrt.JCRT_910_18","article-title":"Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: \u201cA sharp sword\u201d","volume":"15","author":"Li","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R13-20260511","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4103\/jcrt.jcrt_255_22","article-title":"The efficacy of PD-1 inhibitors in the maintenance treatment of diffuse large B-cell lymphoma: A single-center retrospective analysis[J]","volume":"18","author":"Wei","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"R14-20260511","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma[J]","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20260511","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing 1-asparaginase[J]","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"R16-20260511","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma[J]","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R17-20260511","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3324\/haematol.2017.182444","article-title":"Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified[J]","volume":"103","author":"Ji","year":"2018","journal-title":"Haematologica"},{"key":"R18-20260511","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4103\/jcrt.JCRT_403_17","article-title":"Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors[J]","volume":"15","author":"Rygiel","year":"2019","journal-title":"J Cancer Res Ther"},{"key":"R19-20260511","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming[J]","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"R20-20260511","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade[J]","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"R21-20260511","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-016-0363-1","article-title":"High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy[J]","volume":"9","author":"Falchi","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R22-20260511","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma[J]","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol"},{"key":"R23-20260511","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4103\/jcrt.JCRT_1606_20","article-title":"Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1\/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials[J]","volume":"17","author":"Huang","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"R24-20260511","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1126\/science.aae0491","article-title":"The epigenetic landscape of T cell exhaustion[J]","volume":"354","author":"Sen","year":"2016","journal-title":"Science"},{"key":"R25-20260511","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: An open-label, multicenter, randomized controlled trial[J]","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"key":"R26-20260511","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1158\/1078-0432.CCR-17-1201","article-title":"Increased IFNy+T cells are responsible for the clinical responses of low-dose DNA-demethylating agent decitabine antitumor therapy[J]","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R27-20260511","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1158\/1078-0432.CCR-21-0133","article-title":"Efficacy of decitabine plus anti-PD-1 camrelizumab in patients with Hodgkin lymphoma who progressed or relapsed after PD-1 blockade monotherapy[J]","volume":"27","author":"Wang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R28-20260511","doi-asserted-by":"crossref","first-page":"693023","DOI":"10.3389\/fmed.2021.693023","article-title":"Case Report: PD-1 blockade combined autologous hematopoietic stem cell transplantation with modified BEAM regimen containing high-dose cytarabine to treat R\/R Hodgkin\u2019s lymphoma[J]","volume":"8","author":"Wang","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1458_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:25:14Z","timestamp":1786724714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1458_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1458_22","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"2022-07-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}